ValuEngine upgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a buy rating in a research report released on Friday.

Several other equities analysts have also issued reports on CELC. HC Wainwright initiated coverage on Celcuity in a research report on Tuesday, November 20th. They issued a buy rating and a $36.00 price objective for the company. Zacks Investment Research upgraded Celcuity from a hold rating to a buy rating and set a $26.00 price objective for the company in a research report on Thursday, February 28th.

Shares of CELC opened at $20.07 on Friday. Celcuity has a 52-week low of $13.16 and a 52-week high of $31.00. The company has a market capitalization of $209.18 million, a P/E ratio of -27.12 and a beta of 0.24.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in Celcuity by 1.6% during the 3rd quarter. BlackRock Inc. now owns 291,411 shares of the company’s stock worth $8,381,000 after acquiring an additional 4,604 shares during the last quarter. Vanguard Group Inc. boosted its position in Celcuity by 59.8% during the 3rd quarter. Vanguard Group Inc. now owns 259,900 shares of the company’s stock worth $7,475,000 after acquiring an additional 97,266 shares during the last quarter. Vanguard Group Inc boosted its position in Celcuity by 59.8% during the 3rd quarter. Vanguard Group Inc now owns 259,900 shares of the company’s stock worth $7,475,000 after acquiring an additional 97,266 shares during the last quarter. ARS Investment Partners LLC boosted its position in Celcuity by 48.2% during the 4th quarter. ARS Investment Partners LLC now owns 71,093 shares of the company’s stock worth $1,706,000 after acquiring an additional 23,119 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Celcuity by 2.0% during the 4th quarter. Northern Trust Corp now owns 61,888 shares of the company’s stock worth $1,484,000 after acquiring an additional 1,223 shares during the last quarter. 22.04% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer.

Recommended Story: Dividend Achievers

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.